Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olezarsen in severe hypertriglyceridemia
NCT05552326Phase 3Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Aug 2022
- Primary completion
- Dec 2024
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in hypertriglyceridemia comparing Olezarsen with Placebo (2 arms). Primary endpoint: Fasting Triglycerides at 6 months. Started Aug 2022; status: completed.
02
Drugs
olezarsen
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT05552326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05552326.